Furthermore, treatment with IL-33 alleviated HFD-induced hepatic steatosis, reduced serum alanine aminotransferase (ALT) levels, and ameliorated insulin resistance and glucose intolerance. The gene discussed is IL33; the disease is Insulin resistance.